FDGal PET/CT to Detect Hepatocellular Carcinoma

Hepatocellular Carcinoma Clinical Trial

Official title:

A Single-blind Study to Evaluate the Efficacy and Safety of 18F-Fluorodeoxygalactose (18F-FDGal) Compared to 18F-Fluorodeoxyglucose (18F-FDG) to Detect Hepatocellular Carcinoma Via PET/CT in Patients With Cirrhosis or Chronic Liver Disease

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02899325
• Other study ID #: H16-01905
• Status: Withdrawn
• Start date: October 2019
• Est. completion date: October 2021

Study information

• Verified date: December 2019
• Source: British Columbia Cancer Agency
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Liver cancer is one of the leading causes of cancer death among Asian men. If diagnosed early the disease is treatable with surgery. Current conventional imaging modalities have limitations to early detection. This study proposes to use 18F-FGal and 18F-FDG PET/CT scans to compare the clinical efficacy of diagnosing hepatocellular carcinoma (a type of liver cancer) using these PET/CT scans.

Description:

Screening Visit Patients will undergo screening procedures for determining eligibility prior to the first PET/CT examination. For practical reasons and to avoid unnecessary travel for research subjects, the initial screening can be conducted by phone, and completed on the day that the first PET/CT examination is performed. However, the PET/CT scan will only be done for subjects that meet all the eligibility criteria and sign the consent form prior to the examination. All patients should have received the consent form by mail, email or fax, at least 24 hours prior to the screening visit.

Demographics Demographic data including date of birth, gender, height and weight information will be obtained.

Medical History and Concomitant Medications The general medical history up to 3 months of study entry (screening visit) should be recorded at the screening visit. The medical history should include procedural and surgical history within the past year. Cancer history should be recorded on a lifetime basis. Previous medications should be recorded up to 28 days prior to screening visit and up to 1 year for cancer treatment if any. All concomitant medications starting from enrollment of subjects should be recorded on subsequent visits for the PET/CT examinations.

Vital Signs Patient's vital signs will be measured including blood pressure, pulse rate and oxygen saturation, within 60 minutes before and 5-15 minutes after administration of the investigational product at PET/CT visits.

PET/CT Scans Patients who meet all eligibility requirements for entry into the study will undergo both an 18F-FDGal and 18F-FDG PET/CT examinations at the BCCA - Vancouver Centre's Functional Imaging Department. The two scans are to be performed on separate days and must be performed between 1 and 15 calendar days of each other. Each PET/CT scan will require approximately 3 hours of additional time from the subject above standard of care. The screening visit and informed consent, can be performed on the same day as the first PET/CT scan (and before the examination), will take approximately one hour.

Prior to the PET/CT scans, subjects will be instructed to take their usual medications as prescribed by their family physician. Subjects will also be instructed to drink 3 to 4 glasses of water within two hours prior to their scan appointment in order to promote hydration and facilitate urinary clearance of background 18F-FDGal/18F-FDG. Subjects must fast for 6 hours prior to 18F-FDGal and 18F-FDG injection, but can drink water at will.

Upon arrival at the PET Imaging department, all subjects will have their weight recorded prior to 18F-FDGal/18F-FDG injection. A baseline blood pressure, heart rate, and oxygen saturation levels will be recorded within 60 minutes prior to 18F-FDGal/18F-FDG injection, and 5 - 15 minutes after injection.

Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of 18F-FDGal/18F-FDG from the BCCA, at a dose of 237 - 521 MBq for 18F-FDG and 119 - 261 MBq MBq for 18F-FDGal, followed by a 5 - 20 mL normal saline flush. The subject will rest in a comfortable chair for 60 minutes.

Upon completion of the scan, subjects will be free to leave the department and will be encouraged to drink 3-4 extra glasses of water by the end of the day to promote further clearance of the remaining tracer in the urinary tract. Overall, the study will take approximately 3 hours of subject time.

Each patient will be monitored on vital signs, adverse events before and after the intravenously 18F-FDGal/18F-FDG administration. Concomitant medication(s) will also be recorded. All of the 18F-FDGal/18F-FDG PET/CT imaging obtained at all study will be sent to a centralized location in DVD sets for re-labeling purpose to mask the patients' identifiers from readers.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 2021
• Est. primary completion date: October 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• Male or female, age = 19 years of age.

• Patient who accepts to enter the study by signing written informed consent.

• Patient with performance status = 2 Eastern Cooperative Oncology Group (ECOG).

• Patient with cirrhosis or chronic liver disease suspected to have at least 1 hepatic nodule larger than 1 cm in diameter detected by conventional image (US, CT, MRI).

• Hepatic nodule is defined as any one of the following conditions: suspicious hepatocellular carcinoma, benign tumor such as hemangioma, adenoma or focal nodular hyperplasia, possible metastatic lesions from other primary malignancy.

Exclusion Criteria:

• Patient has serious allergic history or known allergy to 18F-FDGal or 18F-FDG.

• Patient has received therapy for aforementioned diagnosis before the PET scans

• Patient with known (proven) metastases from a prior malignancy

• Patient has been diagnosed with multiple malignancies.

• Female patient who is pregnant, lactating or planning to become pregnant during the study.

• Patient has participated in other investigational trials within 28 days prior to study enrollment.

• Inability to lie supine for the duration of the imaging studies.

• Subject with active systemic infections, or medical conditions that may significantly affect adequate uptake and elimination of radiotracer.

• Subject with conditions judged by the investigator as unsuitable for the study.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Chronic Liver Disease
• Fibrosis
• Hepatocellular Carcinoma
• Liver Cirrhosis
• Liver Diseases

Intervention

Drug:
• Diagnostic PET/CT scans
These PET/CT scans will be performed for diagnostic purposes of hepatocellular carcinoma.

Locations

Country	Name	City	State
Canada	BC Cancer Agency	Vancouver	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
British Columbia Cancer Agency

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity of 18F-FDGal in the diagnosis of HCC on per-patient basis	Determination of sensitivity of both exams when compared with pathology reports (if available) and compared with routine imaging (CT, MRI, US) if available. The treatment group will be declared superior if the lower limit of the 95% two-sided confidence interval of the difference of these two proportions is greater than 0.	6 months
Secondary	Number of participants with 18F-FDGal-related adverse events as assessed by abnormal vital sign measurement	Vital signs (blood pressure, heart rate and pulse oximetry) will be measured at three time points (before and after injection, and 1 hour after the injection). All values that fall outside of the normal parameters will be assessed by a physician and reported as an adverse event.	1 hour
Secondary	Sensitivity of 18F-FDGal in the diagnosis of HCC on per-site basis	Determination of sensitivity of both exams when compared with pathology reports (if available) and compared with routine imaging (CT, MRI, US) if available. The treatment group will be declared superior if the lower limit of the 95% two-sided confidence interval of the difference of these two proportions is greater than 0.	6 months
Secondary	Specificity of 18F-FDGal in the diagnosis of HCC	Specificity of 18F-FDGal and 18F-FDG PET/CT are calculated on per-patient and per-site basis (site=lesion).	6 months